Pioneering biologics with precision—to redefine treatment for millions
Fortvita is focused on investigating biologics with smarter design and agile innovation, with the goal of translating next-generation therapies from concept to clinic.
What We Do
Pursuing scientific solutions for global healthcare needs
Antibody innovation is central to our mission to advance biologic therapies for patients worldwide. Through protein engineering, structure-based drug design, and bispecific antibody technologies, we are investigating next-generation treatments aimed at addressing limitations of current standards of care. Our global vision is to make groundbreaking science accessible, turning research into real-world solutions that improve health outcomes for those who need them most.
Pipelines
Pipelines designed with focused innovation
Our pipeline reflects a deliberate approach to biologic innovation, with programs exploring novel mechanisms in immunotherapy and targeted delivery. Current molecules include bispecific antibodies and ADCs directed at PD-1, IL-2, DLL3, CLDN18.2, and others, with clinical and preclinical development across tumor types such as lung, gastric, pancreatic, colorectal, and melanoma.
Our Mission
Transforming research breakthroughs into therapeutic excellence
We’re a biopharma company based in the San Francisco Bay Area with a global presence, specializing in antibody discovery and engineering. Our clinical trials span Australia, China, and the U.S., investigating innovative biologics in challenging cancers, including lung, pancreatic, and gastroesophageal cancers. Driven by a commitment to improving patient outcomes, we focus on delivering targeted solutions with the goal of enhancing the lives of patients and their communities.
